Logo

Allogene Therapeutics, Inc.

ALLO

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The compan… read more

Healthcare

Biotechnology

7 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$1.84

Price

-2.13%

-$0.04

Market Cap

$635.085m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financial Reports

Key metrics over the past few years and other important metrics. Amounts in USD.

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$0.00

-

1y CAGR

-58.9%

3y CAGR

-54.0%

5y CAGR
Earnings

-$173.760m

+9.0%

1y CAGR

+18.7%

3y CAGR

+15.0%

5y CAGR
EPS

-$0.77

+11.5%

1y CAGR

+27.5%

3y CAGR

+23.7%

5y CAGR
Book Value

$278.875m

$395.958m

Assets

$117.083m

Liabilities

$81.051m

Debt
Debt to Assets

20.5%

-0.5x

Debt to EBITDA
Free Cash Flow

-$109.526m

+26.8%

1y CAGR

+22.8%

3y CAGR

+15.6%

5y CAGR
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases